• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Repro-Med updates on FDA warning letter over Freedom Infusion sets

March 21, 2016 By Fink Densford

Repro-Med SystemsRepro-Med Systems last Friday updated on a warning letter it received in February over issues the FDA found with the company’s Freedom 60 syringe infusion pump and Freedom Edge infusion pumps.

The company said it submitted a response to the warning letter last Friday to the FDA, 3 days before the required response date set by the federal watchdog.

Repro-Med said the letter responded “in great detail” to the issues brought up in the letter from the FDA, but said it would not publish the response letter due to proprietary details required to complete the response.

The company said there were no safety concerns raised in the response, and that it has not been requested to withdraw any products from the market, according to an SEC filing.

Earlier this month, Repro-Med responded to the initial letter and said it would respond hastily to the issues the agency had.

The letter was in response to an earlier reply from Repro-Med, which the FDA said was “not adequate” for handling the issues it raised, as well as laying out several aspects of the devices that were being mis-marketed, as well as failures in quality control and medical device reporting.

In the response letter, the federal watchdog said that the company’s Freedom 60 syringe and Freedom Edge infusion pumps were misbranded due to modifications made to the system.

Filed Under: Drug-Device Combinations Tagged With: Repro-Med Systems Inc.

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS